HeFangTian Venture Partnership

HeFangTian Venture Partnership is a venture capital firm that invests in early-stage biotechnology and life sciences companies, with a strategic focus on innovative therapies in oncology and cell therapy. The firm provides crucial funding to support the development of advanced medical solutions, particularly those involving gene-edited products for solid tumors and other high-impact areas within healthcare. Operating through a typical limited partnership structure, HeFangTian identifies and backs promising ventures poised for significant growth and therapeutic breakthroughs. The firm has notably invested in Grit Biotechnology, participating in its $60 million Series B financing round in September 2023. This investment contributed to Grit Biotechnology's total funding of $75.27 million across its various rounds. HeFangTian frequently co-invests alongside prominent entities such as CICC, Sherpa Healthcare Partners, Decheng Capital, and Matrix Partners China, leveraging a robust network within the life sciences investment landscape.